Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.

•Proper use of standard antiemetic therapy for docetaxel–cyclophosphamide provides a high chemotherapy-induced nausea and vomiting (CINV) control rate.•Aprepitant as secondary prophylaxis induced a high CINV control rate.•The absence of good CINV control rate negatively impacts quality of life.